Why Azenta, Inc.’s (AZTA) Stock Is Down 5.43%
As of Monday, November 02, Azenta, Inc.’s AZTA share price has dipped by 5.43%, which has investors questioning if this is right time to buy.Tudor Pop
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Azenta, Inc. provides biological and chemical compound sample exploration and management solutions for the life sciences industry in the United States, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. It operates through Sample Management Solutions and Multiomics segments. The Sample Management Solutions segment provides sample management products and services, including automated stores, cryogenic systems, automated sample tubes, consumables and instruments, and controlled rate thawing devices, as well as sample repository services. This segment also offers consultation services to clients throughout their experimental design and implementation processes. The Multiomics segment provides genomic and other sample analysis services comprising gene sequencing, gene synthesis, and related services. The company has a strategic partnership with Frontier Space Ltd to conduct scientific experiments in space. The company was formerly known as Brooks Automation, Inc. and changed its name to Azenta, Inc. in December 2021. Azenta, Inc. was founded in 1978 and is headquartered in Burlington, Massachusetts.
Commentary & Analysis
Why Azenta, Inc.’s (AZTA) Stock Is Down 5.88%
As of Friday, October 30, Azenta, Inc.’s AZTA share price has dipped by 5.88%, which has investors questioning if this is right time to buy.Tudor Pop
Why Azenta, Inc.’s (AZTA) Stock Is Down 6.27%
As of Friday, October 16, Azenta, Inc.’s AZTA share price has dipped by 6.27%, which has investors questioning if this is right time to buy.Michael Rose
Why Azenta, Inc.’s (AZTA) Stock Is Up 5.08%
As of Friday, October 09, Azenta, Inc.’s AZTA share price has surged by 5.08%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Azenta, Inc.’s (AZTA) Stock Is Down 6.79%
As of Wednesday, October 07, Azenta, Inc.’s AZTA share price has dipped by 6.79%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Financial Summary
| Share Statistics | AZTA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,637.6 | $3,600.2 | 52% |
|
| Shares Out (Mil) | 45.3 | 104.0 | 45% |
|
| Institutional Ownership | 99.4% | 88.4% | 88% |
|
| Float (Mil) | 38.9 | 80.8 | 41% |
|
| Beta | 1.38 | 1.16 | 78% |
|
| Avg Daily Volume (000s) | 922 | 1,133 | 67% |
|
| Price Change (52-week) |
23.9% | 82.6% | 72% |
|
| Growth | AZTA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 8.9% | 7.5% | 54% |
|
| Net Income (5yr) | (23.4%) | (12.1%) | 17% |
|
| EPS (5yr) | (27.7%) | 2.1% | 9 |
|
| Dividends (5yr) | (14.9%) | 0.0% | 0% |
|
| Cash Flow (5yr) | (67.7%) | (14.9%) | 3% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 6 | 6 | 5 | |
| Current EPS | $0.112 | $0.318 | $0.526 | |
| Month Ago EPS | $0.128 | $0.333 | $0.553 | |
| # Rev Up | 0 | 0 | 1 | |
| # Rev Down | 1 | 2 | 0 | |
| Three Months Ago EPS | $0.164 | $0.370 | $0.590 | |
| Year/Year Chg | (429.4%) | (40.0%) | 29.8% | |
| Financials | AZTA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $614 | $811 | 43% |
|
| Net Income (TTM) (Mil) | ($123) | ($31) | 10% |
|
| EPS (TTM) | ($2.685) | ($0.300) | 12% |
|
| Operating Cash Flow (TTM) (Mil) | $38 | $56 | 44% |
|
| Net Cash Flow (TTM) (Mil) | ($89) | $19 | 16% |
|
| Long-Term Debt (Q1) (Mil) | $54 | $274 | 39% |
|
| Enterprise Value (Q1) (Mil) | $936 | $3,486 | 40% |
|
| Valuation | AZTA | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.08 | 3.33 | 30% |
|
| P/E | na | 35.7 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 6.3 | na |
|
| Ratios | AZTA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 44.0% | 47.6% | 55% |
|
| Net Margin | (20.0%) | (3.0%) | 16% |
|
| ROA | (6.3%) | (4.9%) | 28% |
|
| ROE | (7.7%) | (7.7%) | 28% |
|
| Liabilities to Assets | 19.5% | 41.1% | 13% |
|
| F-Score | 4 | 5 | 33% |
|
Passing Stock Screens
As of 11/5/2026, from a list of 60 stock screening strategies,
FACTOR STRATEGY
Price-to-Sales Screen
Factors: Value, Growth
Research indicates that using price-to-sales ratios may lead to better investment results than price-to-book-value ratios or price-earnings ratios.
| Performance Since Inception: | 13.1% |
| +/- S&P 500: | +5.7 |
